Literature DB >> 11706113

Clinical features of withdrawal headache following overuse of triptans and other headache drugs.

Z Katsarava1, G Fritsche, M Muessig, H C Diener, V Limmroth.   

Abstract

BACKGROUND: Complete withdrawal from headache medication is the treatment of choice for medication-overuse headache. Discontinuation of the overused headache medication, however, results in the development of withdrawal headache, often associated with nausea, vomiting, and sleep disturbances.
METHOD: In a prospective study of 95 patients, the authors investigated the duration and severity of withdrawal headache after overuse of various headache drugs, including single and combination analgesics, ergots, and triptans. All patients underwent standard inpatient withdrawal therapy for 14 days.
RESULTS: The duration of withdrawal headache was shorter in patients overusing triptans (4.1 days) than in patients overusing ergots (6.7 days) or analgesics (9.5 days; p < 0.002). The mean headache intensity on the first day of withdrawal did not differ between the groups (p = 0.821). By day 14, however, it was lower in patients overusing triptans (0.08) than in patients overusing ergots (0.4) or analgesics (0.9; p < 0.005). Rescue medication was requested less by patients undergoing triptan withdrawal (0.25 requests) than by patients undergoing ergot withdrawal (1.25) or analgesic withdrawal (1.85; p < 0.05). Similar to findings in the entire patient population, withdrawal headache was shorter and less severe in migraineurs overusing triptans than in those overusing ergots or analgesics. Because only patients with migraine, but no patient with tension-type headache, overused triptans, withdrawal headache was shorter in the group of patients with migraine alone (6.7 days versus 9.6 days for patients with tension-type headache and 8.5 days for patients with combination headache, p < 0.02).
CONCLUSION: The duration and severity of withdrawal clearly depend on the type of overused headache drug only.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11706113     DOI: 10.1212/wnl.57.9.1694

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  53 in total

Review 1.  Psychiatric comorbidity in chronic daily headache: pathophysiology, etiology, and diagnosis.

Authors:  Vincenzo Guidetti; Federica Galli
Journal:  Curr Pain Headache Rep       Date:  2002-12

Review 2.  Medication overuse headache.

Authors:  Valerie Cheung; Farnaz Amoozegar; Esma Dilli
Journal:  Curr Neurol Neurosci Rep       Date:  2015-01       Impact factor: 5.081

Review 3.  Cortical excitability in chronic migraine.

Authors:  Gianluca Coppola; Jean Schoenen
Journal:  Curr Pain Headache Rep       Date:  2012-02

Review 4.  [Gordian knot: medication overuse headache].

Authors:  Z Katsarava; G Fritsche
Journal:  Schmerz       Date:  2004-10       Impact factor: 1.107

Review 5.  Update on medication-overuse headache.

Authors:  Milena De Felice; Michael H Ossipov; Frank Porreca
Journal:  Curr Pain Headache Rep       Date:  2011-02

Review 6.  Medication overuse headache in patients with primary headache disorders: epidemiology, management and pathogenesis.

Authors:  Andrew J Dowson; David W Dodick; Volker Limmroth
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

Review 7.  Tension-type headache with medication overuse: pathophysiology and clinical implications.

Authors:  Teshamae S Monteith; Michael L Oshinsky
Journal:  Curr Pain Headache Rep       Date:  2009-12

Review 8.  Tolerability of the triptans: clinical implications.

Authors:  Giuseppe Nappi; Giorgio Sandrini; Grazia Sances
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

9.  Triptans disrupt brain networks and promote stress-induced CSD-like responses in cortical and subcortical areas.

Authors:  L Becerra; J Bishop; G Barmettler; Y Xie; E Navratilova; F Porreca; D Borsook
Journal:  J Neurophysiol       Date:  2015-10-21       Impact factor: 2.714

10.  Topiramate in migraine prophylaxis--results from a placebo-controlled trial with propranolol as an active control.

Authors:  Hans-Christoph Diener; Peer Tfelt-Hansen; Carl Dahlöf; Miguel J A Láinez; Giorgio Sandrini; Shuu-Jiun Wang; Walter Neto; Ujjwalla Vijapurkar; Aiden Doyle; David Jacobs
Journal:  J Neurol       Date:  2004-08       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.